Ndufa6 regulates adipogenic differentiation via Scd1

Jingwei Zhang; Wei Wang; Ninghan Feng; Xuan Jiang; Shenglong Zhu; Yong Q Chen

doi:10.1080/21623945.2021.2007590

Ndufa6 regulates adipogenic differentiation via Scd1

Adipocyte. 2021 Dec;10(1):646-657. doi: 10.1080/21623945.2021.2007590.

Authors

Jingwei Zhang, Wei Wang¹, Ninghan Feng^{1

2}, Xuan Jiang, Shenglong Zhu^{1

3}, Yong Q Chen^{1

3}

Affiliations

¹ Department of metabolism, Wuxi School of Medicine, Jiangnan University, Wuxi, China.
² Department of Urology the Wuxi No. 2 People's Hospital, Wuxi 214002 China.
³ Wuxi Translational Medicine Research Center and Jiangsu Translational Medicine Research Institute, Wuxi, China.

Abstract

Obesity and associated complications are becoming a pandemic. Inhibiting adipogenesis is an important intervention for the treatment of obesity. Despite intensive investigations, numerous mechanistic aspects of adipogenesis remain unclear, and many potential therapeutic targets have yet to be discovered. Transcriptomics and lipidomics approaches were used to explore the functional genes regulating adipogenic differentiation and the potential mechanism in OP9 cells and adipose-derived stem cells. In this study, we found that NADH:ubiquinone oxidoreductase subunit A6 (Ndufa6) participates in the regulation of adipogenic differentiation. Furthermore, we show that the effect of Ndufa6 is mediated through stearoyl-CoA desaturase 1 (Scd1) and demonstrate the inhibitory effect of a SCD1 inhibitor on adipogenesis. Our study broadens the understanding of adipogenic differentiation and offers NDUFA6-SCD1 as a potential therapeutic target for the treatment of obesity.

Keywords: Ndufa6; Obesity; Scd; adipogenic differentiation.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Adipocytes
Adipogenesis*
Adipose Tissue
Cell Differentiation
Stearoyl-CoA Desaturase*

Substances

Stearoyl-CoA Desaturase

Grants and funding

This work was supported by the National Key Research and Development Program of China (Grant No. 2017YFD0400200), the National Natural Science Foundation of China (Grant Nos. 31771539 [YQ.C], 82000808 [SL,Z]), the Innovation and Application Project of Medical and Public Health Technology of Wuxi Science and Technology (N20202005), the Major Special Fund for Translational Medicine (major special fund for translational medicine 2020ZHZD03), the Fundamental Research Funds for the Central Universities (JUSRP12048) and the key Research and Development Program of Jiangsu province (Grant No. key research and development program of jiangsu province BE2018624).